The present invention relates to novel benzopyran ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory, bowel disease, and arthritis. Formula (I), wherein G is --O--, --S(O)--, --CF.sub.2--, --C(O)--, --CR.sup.1H-- or --CR.sup.2(OH)--; R is halo, (C.sub.1-C.sub.4)alkyl or R.sup.2--(CH.sub.2).sub.m--; R.sup.1 is F, hydroxyl, cyano, trifluoromethyl, (C.sub.1-C.sub.4)alkyl, (C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.4)alkycarbonyloxy or benzyl; R.sup.2 is trifluoromethyl or (C.sub.1-C.sub.4)alkyl; R.sup.3 is cyano, hydroxyl, (C.sub.2-C.sub.4)alkenyl, (C.sub.1-C.sub.4)alkoxy or (C.sub.1-C.sub.4)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.